Replies to post #112193 on Biotech Values

[DewDiligence]

The reference is based on the stock price not the product price so let's keep the conversation straight… As you can see, it certainly isn't its earnings that caused the price recovery. Also keep in mind that your 'starting point' to calculate the recovery is at a multi-year low.

That’s exactly my point—the recent 61% rise in the stock price and the magnitude of the preceding sell-off are evidence of an inefficient stock market.

The stock has been put into favor because of the future demand and pricing expectations of food products.

As stated in the previous posts in this thread, MON does not benefit to a significant degree from higher commodity prices or higher food prices. If this is why the stock in “back in favor,” it’s more evidence of an inefficient stock market.